Ahead Of PTAB Verdict, Viatris And Natco Shake Hands On US Ozempic Settlement
Viatris’ Mylan Has Also Recently Settled Patent Fights In Delaware District Court
The world’s best-selling diabetes medicine, with sales last year across the globe of around $14bn, is now in the crosshairs in the US for Viatris’ Mylan and its partner Natco, after the firms announced an agreement settling litigation that was pending before the US Patent and Trademark Office’s Patent Trial and Appeal Board.
